摘要
目前,我国药品监督管理机构正在推行“渐进式的医药分业”政策,目标是将药品价格总体下降26%～30%,将每年469亿元～547亿元的药品毛利化作医疗服务收费标准的调整幅度,以后医疗服务收费标准按物价指数逐年调整。但在现有条件下执行这一政策,表面上医疗机构是直接的利益受损者,但事实上广大的药品消费者或支付者将为之埋单而成为利益受损者,药品生产者和流通渠道才是这一政策的真正受益者,政府也将面临提高医疗服务收费标准或增加医疗机构补偿的两难抉择。
The policy of “advancing gradually type medicine industry and drugs industry separated” is carried out by drugs surveillance management institution in our country, the goal is to drop the drugs price overall by 26% -30%, every year 46.9 billion - 54.7 billion yuan as gross profits is the medical service charge standard for tuning band, medical service charge standard will be ad- justed year by year according to the price index later, on the surface of medical establishment is direct benefit suffering injury, but the general drugs consumers or the payers who bury the list for it are becoming benefit suffering injury, the drugs producer and the circulation channel will be genuine beneficiary under the existing condition. The government also faces a dilemma choice of enhancing the medical service charge standard or increacsing medical establishment compensates.
出处
《医学与哲学》
北大核心
2005年第12S期42-43,47,共3页
Medicine and Philosophy
关键词
渐进式
医药分业
利益受损者
经济分析
gradually
medicine industry and drugs industry separated
benefit suffering injury
economic analysis
作者简介
林辉（1955-），女，副教授，东南大学医学人文系主任，研究方向：医学哲学与医学心理学。
